Want to see HK:2289 full AI Analyst Report?
2289 Stock Chart & Stats
HK$7.31
HK$0.00(0.00%)
At close: 4:00 PM EST
HK$7.31
HK$0.00(0.00%)
Day’s Range― - ―
52-Week RangeHK$4.30 - HK$8.00
Previous CloseN/A
Volume50.00K
Average Volume (3M)33.00
Market Cap
HK$593.46M
Enterprise ValueHK$2.42K
Total Cash (Recent Filing)HK$753.92M
Total Debt (Recent Filing)HK$2.09B
Price to Earnings (P/E)10.9
Beta-0.22
Next Earnings
Mar 26, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield6.25%
Share Statistics
EPS (TTM)0.42
Shares Outstanding108,000,000
10 Day Avg. Volume50
30 Day Avg. Volume33
Financial Highlights & Ratios
PEG Ratio-1.24
Price to Book (P/B)1.15
Price to Sales (P/S)0.16
P/FCF Ratio2.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Steady Revenue GrowthSteady sales with renewed growth indicate continued demand and a durable operating base. Although the pace is modest, maintaining revenue while expanding gross margin can support incremental earnings improvement and provide a foundation for disciplined growth over the next several quarters.
Improving Gross MarginThe multiyear improvement in gross margin suggests better profitability per unit of revenue and some strengthening in the economics of the business. If retained, this progress can help offset modest sales growth, improve operating resilience, and support more durable cash generation.
Strong Recent Cash GenerationStrong operating and free cash flow in 2025 indicates that reported earnings were supported by cash conversion rather than being purely accounting-based. This gives the company greater capacity to fund operations, service obligations, and make investments without relying entirely on external financing.
Bears Say
Materially Higher LeverageRapidly higher debt relative to largely flat equity means balance-sheet expansion is being funded more by borrowing than retained earnings. This increases financial risk, raises the burden on future cash flows, and reduces flexibility if operating performance weakens or funding needs persist.
Thin And Declining Net ProfitabilityVery thin net margins leave limited room to absorb cost pressure, financing expense, or weaker sales. The decline from 2022 profitability and lower 2025 net income also indicate that steady revenue has not translated into durable earnings growth, constraining internal capital formation.
Volatile Cash-Flow ConsistencyThe recent cash improvement is encouraging, but the sharp variation across years reduces confidence that strong conversion will persist consistently. Slightly negative free-cash-flow growth in 2025 further suggests that future debt service and investment capacity may remain uneven.
Charmacy Pharmaceutical Co., Ltd. Class H News
2289 FAQ
What was Charmacy Pharmaceutical Co., Ltd. Class H’s price range in the past 12 months?
Charmacy Pharmaceutical Co., Ltd. Class H lowest stock price was HK$4.30 and its highest was HK$8.00 in the past 12 months.
What is Charmacy Pharmaceutical Co., Ltd. Class H’s market cap?
Charmacy Pharmaceutical Co., Ltd. Class H’s market cap is HK$593.46M.
When is Charmacy Pharmaceutical Co., Ltd. Class H’s upcoming earnings report date?
Charmacy Pharmaceutical Co., Ltd. Class H’s upcoming earnings report date is Mar 26, 2027 which is in 188 days.
How were Charmacy Pharmaceutical Co., Ltd. Class H’s earnings last quarter?
Charmacy Pharmaceutical Co., Ltd. Class H released its earnings results on Aug 31, 2026. The company reported HK$0.238 earnings per share for the quarter.
Is Charmacy Pharmaceutical Co., Ltd. Class H overvalued?
According to Wall Street analysts Charmacy Pharmaceutical Co., Ltd. Class H’s price is currently Overvalued.
Does Charmacy Pharmaceutical Co., Ltd. Class H pay dividends?
Charmacy Pharmaceutical Co., Ltd. Class H pays a Annually dividend of HK$0.344 which represents an annual dividend yield of 6.25%. See more information on Charmacy Pharmaceutical Co., Ltd. Class H dividends here
What is Charmacy Pharmaceutical Co., Ltd. Class H’s EPS estimate?
Charmacy Pharmaceutical Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Charmacy Pharmaceutical Co., Ltd. Class H have?
Charmacy Pharmaceutical Co., Ltd. Class H has 108,000,000 shares outstanding.
What happened to Charmacy Pharmaceutical Co., Ltd. Class H’s price movement after its last earnings report?
Charmacy Pharmaceutical Co., Ltd. Class H reported an EPS of HK$0.238 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Charmacy Pharmaceutical Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2289
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Charmacy Pharmaceutical Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-3.15%
12-Months-Change
Fundamentals
Return on Equity
6.25%
Trailing 12-Months
Asset Growth
18.67%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Charmacy Pharmaceutical Co., Ltd. Class H
Charmacy Pharmaceutical Co., Ltd. serves as a prominent distributor of pharmaceutical products across the People's Republic of China. The company's comprehensive portfolio includes Western medications, traditional Chinese patent medicines, and various healthcare items, along with associated advisory services. These are supplied to both wholesale distributors and retail pharmacies. Furthermore, Charmacy operates "Charmacy e-Medicine," its proprietary B2B digital platform, which enables clients to efficiently place orders, make inquiries, and process payments online. Founded in 1984, the firm maintains its headquarters in Shantou, PRC. It was formerly known as Chuangmei Pharmaceutical Co., Ltd. until its official renaming to Charmacy Pharmaceutical Co., Ltd. in July 2016.
Technical Analysis
China Health Group
―
Shanghai Pharmaceuticals Holding Co
―
Sinopharm Group Co
―
IVD Medical Holding Limited
―
Medlive Technology Co., Ltd.
―